Targeting Epstein-Barr virus–transformed B lymphoblastoid cells using antibodies with T-cell receptor–like specificities
- 8 September 2016
- journal article
- Published by American Society of Hematology in Blood
- Vol. 128 (10), 1396-1407
- https://doi.org/10.1182/blood-2016-03-707836
Abstract
Key Points Anti-EBV TCR-like monoclonal antibodies reduce BLCLs tumor load in vivo. Anti-EBV TCR-like monoclonal antibodies mediate phagocytosis of BLCLs by macrophages.Keywords
This publication has 48 references indexed in Scilit:
- Defining the expression hierarchy of latent T-cell epitopes in Epstein-Barr virus infection with TCR-like antibodiesScientific Reports, 2013
- T-Cell Receptor-Like Antibodies: Targeting the Intracellular Proteome Therapeutic Potential and Clinical ApplicationsAntibodies, 2013
- Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantationBlood, 2012
- Successful Treatment of a Patient With Epstein-Barr Virus–Positive B-Cell Lymphoproliferative Disorder Resembling Post-Transplant Lymphoproliferative Disorder Using Single-Agent RituximabJournal of Clinical Oncology, 2011
- An anti–PR1/HLA-A2 T-cell receptor–like antibody mediates complement-dependent cytotoxicity against acute myeloid leukemia progenitor cellsBlood, 2011
- Targeting Hepatitis B Virus-Infected Cells with a T-Cell Receptor-Like AntibodyJournal of Virology, 2011
- Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipientsBlood, 2010
- TCR Mimic Monoclonal Antibody Targets a Specific Peptide/HLA Class I Complex and Significantly Impedes Tumor Growth In Vivo Using Breast Cancer ModelsThe Journal of Immunology, 2010
- How I treat EBV lymphoproliferationBlood, 2009
- Rituximab therapy is effective for posttransplant lymphoproliferative disorders after solid organ transplantationCancer, 2005